Management of Hepatitis C Infection
Summary
- High SVR12 rates observed with 12 weeks of sofosbuvir/velpatasvir in phase III trials
- ASTRAL-1: SVR12 99% in genotype 1, 2, 4, 5, 6 HCV infection[Feld 2015]
- ASTRAL-2: SVR12 99% vs 94% with 12-wks of sofosbuvir + ribavirin in genotype 2 HCV infection[Foster 2015]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content
Keywords: Hepatitis C-Treatment